Tildrakizumab for the treatment of psoriasis
Author:
Affiliation:
1. Department of Medicine, University of Melbourne, Melbourne, Australia
2. Curtin Medical School, Curtin University, Perth, Australia
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2019.1544493
Reference39 articles.
1. Efficacy and safety of emerging immunotherapies in psoriasis
2. Psoriasis pathogenesis and the development of novel targeted immune therapies
3. Treatment Approaches to Moderate to Severe Psoriasis
4. Current and future management of psoriasis
5. Guidelines of care for the management of psoriasis and psoriatic arthritis
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel Approaches and Applications of Nanotechnology in the Delivery of Topical Drugs for Psoriasis via Nanocarriers;Current Nanoscience;2024-08-23
2. An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis;Current Drug Targets;2024-04
3. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data;Clinical, Cosmetic and Investigational Dermatology;2023-09
4. Identification of Biological Risk Genes and Candidate Drugs for Psoriasis Vulgaris by Utilizing the Genomic Information;Borneo Journal of Pharmacy;2023-05-31
5. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa;International Journal of Molecular Sciences;2023-05-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3